CrossBridge Bio
PrivateLast Round
Grant
Nov 20, 2025
Total Funding Raised
$12.6M
Momentum Score
50 /100
Company Overview
CrossBridge Bio is a biotechnology company that develops next-generation dual-payload antibody-drug conjugates (ADCs) to overcome tumor resistance and heterogeneity.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CrossBridge Bio Comps
Public and private peers based on sector, stage, and business model.
CrossBridge Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 20, 2025 | ||||
| Seed | Nov 4, 2024 | ||||
| Grant | May 15, 2024 |
Key People
Founding team and executive leadership
CrossBridge Bio Investors
Notable investors and investment history
Market signals
Structured signals derived from secondary market and firmographic data.
- May 13, 2026
Monthly visitors increased 37% MoM.
- Apr 15, 2026
Acquired by Eli Lilly for up to $300 million.
CrossBridge Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about CrossBridge Bio's valuation, stock price, and market status.
